Danske Bank A S Has $25.81 Million Stake in ResMed Inc. $RMD

Danske Bank A S trimmed its holdings in ResMed Inc. (NYSE:RMD) by 33.7% in the fourth quarter, Holdings Channel reports. The fund owned 107,136 shares of the medical equipment provider’s stock after selling 54,410 shares during the period. Danske Bank A S’s holdings in ResMed were worth $25,806,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in ResMed by 1.6% in the third quarter. Vanguard Group Inc. now owns 19,040,440 shares of the medical equipment provider’s stock valued at $5,211,940,000 after purchasing an additional 293,515 shares in the last quarter. Nordea Investment Management AB grew its stake in ResMed by 37.2% in the fourth quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider’s stock valued at $262,027,000 after purchasing an additional 294,124 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in ResMed by 6.2% in the third quarter. Dimensional Fund Advisors LP now owns 846,134 shares of the medical equipment provider’s stock valued at $231,587,000 after purchasing an additional 49,540 shares in the last quarter. Caisse de depot et placement du Quebec grew its stake in ResMed by 28.0% in the third quarter. Caisse de depot et placement du Quebec now owns 565,901 shares of the medical equipment provider’s stock valued at $154,904,000 after purchasing an additional 123,781 shares in the last quarter. Finally, Captrust Financial Advisors grew its stake in ResMed by 5.4% in the third quarter. Captrust Financial Advisors now owns 537,623 shares of the medical equipment provider’s stock valued at $147,164,000 after purchasing an additional 27,565 shares in the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RMD has been the subject of a number of analyst reports. Evercore set a $255.00 price target on ResMed and gave the company an “outperform” rating in a research note on Monday, April 13th. Robert W. Baird set a $225.00 price target on ResMed in a research note on Friday. Citigroup decreased their price target on ResMed from $345.00 to $340.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Stifel Nicolaus raised their price target on ResMed from $260.00 to $265.00 and gave the company a “hold” rating in a research note on Friday, January 30th. Finally, KeyCorp dropped their price objective on ResMed from $302.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, ResMed has an average rating of “Moderate Buy” and a consensus target price of $286.18.

ResMed Price Performance

Shares of NYSE RMD opened at $205.17 on Friday. The firm has a market cap of $29.89 billion, a P/E ratio of 19.79, a price-to-earnings-growth ratio of 1.35 and a beta of 0.85. The company has a current ratio of 3.06, a quick ratio of 2.32 and a debt-to-equity ratio of 0.06. ResMed Inc. has a 1-year low of $198.64 and a 1-year high of $293.81. The business’s 50 day moving average is $233.35 and its 200-day moving average is $246.50.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.07. The company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.42 billion. ResMed had a return on equity of 25.72% and a net margin of 27.44%.The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.37 earnings per share. Equities research analysts predict that ResMed Inc. will post 11.07 earnings per share for the current year.

ResMed Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th will be paid a dividend of $0.60 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. ResMed’s dividend payout ratio (DPR) is 23.74%.

Insider Buying and Selling

In other news, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $273.78, for a total transaction of $1,366,435.98. Following the transaction, the chief executive officer owned 466,223 shares in the company, valued at approximately $127,642,532.94. This trade represents a 1.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 21,023 shares of company stock worth $5,230,857. 0.65% of the stock is owned by corporate insiders.

More ResMed News

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q3 results beat and margin expansion — ResMed reported revenue up ~11% to ~$1.4B, EPS above consensus, GAAP/non?GAAP gross margins expanded ~290 bps, strong operating cash flow and $262M returned to shareholders via buybacks/dividends. These fundamentals support longer?term earnings growth and cash return potential. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
• Positive Sentiment: Analyst bullish move — Royal Bank of Canada raised its price target to $321 and kept an outperform rating, signaling confidence in ResMed’s growth runway (this raises a sizable upside case). Benzinga
• Positive Sentiment: Dividend maintained and scheduled — Board declared a $0.60 quarterly dividend (ex?div May 14, payable June 18), modest yield but adds to shareholder returns alongside buybacks.
• Neutral Sentiment: New CFO named — CFO Brett Sandercock will retire and Aaron Bloomer is appointed successor. Management continuity reduces execution risk, though investors will watch cadence of financial reporting under new leadership. ResMed beats quarterly profit estimates, names new CFO
• Neutral Sentiment: Strategic commentary and acquisition talk — Earnings call highlighted continued revenue growth drivers and strategic M&A/portfolio moves; useful context for longer?term thesis but not immediate catalysts. ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
• Negative Sentiment: Shares slipped after earnings despite the beat — Market reaction was negative post?release, suggesting investors had higher expectations for guidance, cadence, or near?term execution; volatility may continue as analysts digest details. RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Mixed analyst reaction — Wells Fargo cut its target to $227 and assigned an equal?weight rating, reflecting concern about near?term upside and contributing to selling pressure for investors focused on shorter horizons. Benzinga

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.